It seems to me that if there is a big pharma, or two, in serious negotiations on a partnership/buyout, based on what they currently see as future financial catalysts, then the HIV data would be a secondary issue to a potential CEO's decision to come on board. Data being good would be a clear bonus, but a deal or two with big pharma should be motivation to come on all by itself. Just my view.